Inflammation in Cardiomyopathies: Cellular Mechanisms Across Cardiac Phenotype

Figure 1. Conceptual framework detailing the role of inflammation in the pathogenesis, progression, and clinical outcomes of Hypertrophic Cardiomyopathy (HCM). The schematic illustrates the complex interplay among genetic predisposition, local inflammatory signaling, and structural cardiac remodeling. Left panels: Genetic background and clinical relevance: Primary pathogenic mutations (e.g., affecting β-myosin heavy chain and myosin-binding protein C) induce pathological hypercontractility and impaired diastolic relaxation. This altered biomechanics promotes a chronic, low-grade systemic inflammatory state. Elevated circulating biomarkers—including hs-CRP, various interleukins (IL-1β, IL-6, IL-10, IL-1RA), TNF-α, and an increased neutrophil-to-lymphocyte ratio—strongly correlate with histological fibrosis, disease severity, and a worse prognosis regarding heart failure progression. Central panel: pathophysiological mechanisms: The initial mechanical stress and ischemia inherent to HCM trigger downstream signaling amplification, notably through the upregulation of the NF-κB pathway. This initiates an active, intertwined cascade of cytokine release and fibroblast activation, creating a…

Figure 2. Pathophysiological cascade of inflammation-driven myocardial remodeling in Fabry Disease Cardiomyopathy. The schematic illustrates the progression from primary genetic defect to multi-compartmental cardiac dysfunction. Left panel, primary defect and substrate accumulation: A mutation in the GLA gene leads to alpha-galactosidase A deficiency, causing the systemic and lysosomal accumulation of glycosphingolipids, predominantly globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3). Central panel: secondary Signaling Cascades: These accumulated sphingolipids act as damage-associated molecular patterns (DAMPs), binding to Toll-like receptor 4 (TLR4) on macrophages. This triggers innate immune activation and a chronic, low-grade inflammatory state characterized by the continuous release of pro-inflammatory cytokines (IL-6, TNF-alpha). Parallel secondary processes include elevated oxidative stress (free radical production) and profound mitochondrial dysfunction, contributing to early endothelial impairment. Right panels: Multi-compartmental Cellular Response & Imaging: The inflammatory milieu drives distinct responses across cardiac tissue compartments: (1) cardiomyocytes…

Figure 3. Mechanistic paradigm of inflammation in Cardiac Amyloidosis (CA), elucidating the pathways beyond mechanical stiffening in Light Chain (AL) and Transthyretin (aTTR) subtypes. The schematic highlights the transition from proteotoxicity to systemic and local inflammatory cascades. Left panels: Primary Defects and Proteotoxicity: The pathogenesis involves distinct precursor proteins: in AL amyloidosis, monoclonal plasma cells produce amyloidogenic free light chains (fLCs) which form oligomers and fibrils, with soluble fLCs exerting direct, intrinsic cardiotoxicity. In aTTR amyloidosis, the destabilization of wild-type or mutant transthyretin (TTR) tetramers yields misfolded oligomers that specifically drive immune activation and fibroblast reprogramming. Central panel: Secondary Signaling and Inflammatory Cascades: Early-stage aggregates from both subtypes act as damage-associated molecular patterns (DAMPs). They trigger the NLRP3 inflammasome and activate the NF-κB pathway, leading to Caspase-1 activation and the maturation and release of pro-inflammatory cytokines (e.g., IL-1β, IL-18, IL-6, TNF-α). This molecular cascade promotes severe oxidative stress (free radical generation)…

Figure 4. Comprehensive overview of the pathophysiological mechanisms and the role of inflammation in Arrhythmogenic Cardiomyopathy (ACM), highlighting the transition from genetic etiology to acute inflammatory “hot phases.” The schematic maps the disease trajectory from primary molecular defects to cyclical inflammatory exacerbations and fibrotic remodeling. Top panels: Definition and Genetic Etiology: ACM is a progressive hereditary myocardial disease characterized by epicardial-to-transmural fibro-fatty replacement, progressive wall thinning, and a high risk of ventricular dysfunction, arrhythmias, and sudden cardiac death. The primary pathogenesis is driven by mutations in desmosomal genes (e.g., PKP2, DSP, JUP, DSG2, DSC2), which compromise cell adhesion and lead to myocyte detachment, as well as mutations in non-desmosomal genes (e.g., DES, LMNA, TMEM43, TTNv, FLNC) that disrupt cytoskeletal and nuclear envelope integrity. Bottom left panel: Inflammatory Exacerbations (“Hot Phases”): The clinical progression of ACM is frequently punctuated by episodic, acute inflammatory flares termed “hot phases.” These exacerbations are prominent in juvenile and pediatric populations, are…

Figure 5. The multi-faceted role of inflammation in primary (genetic) and secondary (acquired) dilated cardiomyopathy (DCM). The schematic overview illustrates the distinct pathophysiological pathways, diagnostic features, and clinical outcomes differentiating primary and secondary etiologies of DCM. Left panel (Genetic/Primary DCM): Pathogenic variants in key sarcomeric and structural genes (e.g., TTN truncating variants, LMNA, MYH7, TNNT2, RBM20, BAG3) primarily disrupt cardiomyocyte contractility, leading to secondary maladaptive remodeling and heart failure, typically characterized by lower late gadolinium enhancement (LGE) and relatively higher left ventricular ejection fraction (LVEF). Right panel (Secondary/Acquired DCM): Extrinsic triggers—including viral infections, toxic exposures, chemotherapy, and immune-mediated processes—instigate chronic inflammation and persistent immune responses. This inflammatory cascade induces severe myocardial damage and adverse remodeling, leading to higher LGE and a more pronounced reduction in LVEF. Central panel: Cardiovascular magnetic resonance (CMR) tissue characterization via gadolinium enhancement serves as a pivotal differential diagnostic…

Figure 6. Etiology, immune phases, and diagnostic workflow in inflammatory cardiomyopathy (CMi). CMi is triggered by diverse etiologies (infectious, toxic, autoimmune), causing myocardial inflammation and ventricular remodeling. Pathogenesis progresses from an acute phase (innate immunity, NLRP3 inflammasome activation, IL-1β/IL-18 release) through a subacute phase (adaptive T/B-cell response) to a chronic phase (persistent inflammation leading to dilated cardiomyopathy [DCM] or recovery). Clinically, when conventional CMR is insufficient, endomyocardial biopsy (EMB) with PCR and immunohistochemistry (IHC) guides tailored therapy. Outcomes depend on pathogen virulence, host genetics, and environmental factors.